Etiology and patogenesis of ischemic heart disease
Etiologija i patogeneza ishemijske bolesti srca
Abstract
Ischemic heart disease (IHD) is a condition in which there is an inadequate supply of blood and oxygen to a portion of the myocardium; it typically occurs when there is an imbalance between myocardial oxygen supply and demand. The most common cause of myocardial ischemia is atherosclerotic disease of an epicardial coronary artery (or arteries) sufficient to cause a regional reduction in myocardial blood flow and inadequate perfusion of the myocardium supplied by the involved coronary artery. Although risk factors for atherosclerosis development are largely known, the pathogenesis of disease is still matter of discussion. The investigation during the last decades have provided new date related to the role of endothelial dysfunction, and particularly role of immune cell-mediated mechanisms in pathogenesis of the disease. The data elucidating role of immunopathogenetic mechanisms in the development of atherosclerotic lesions and their complications provided a strong basis for designing a ...new generation of drugs to combat aterosclerosis, and thereby to prevent ischemic heart disease.
Ishemijsku bolest srca karakteriše nedovoljno snabdevenje krvlju, odnosno kiseonikom, dela miokarda. Nastaje onda kada postoji nesklad između količine kiseonika koja se doprema cirkulacijom u miokard i njegovih potreba u kiseoniku. Najčešći uzrok smanjenog snabdevanja krvlju miokarda je aterosklerotska bolest jedne ili više epikardnih koronarnih arterija, koja sužava lumen i, sledstveno smanjuje. Iako su faktori rizika za razvoj ateroskleroze uglavnom poznati mehanizmi razvoja aterosklerotskih promena još uvek nisu u potpunosti razjašnjeni. Poslednje decenije donele su niz novih saznanja, vezanih za ulogu disfunkcije endotela u inicijaciji i progresiji ateroskerotskih promena i posebno za ulogu ćelija imunskog sistema i imunskih mehanizama u patogenezi ovog oboljenja. Saznanja vezana za ulogu imunopatogenetskih mehanizana stvorila su značajnu osnovu za dizajniranje nove generacije lekova za terapiju aterosklerose i time prevencu ishemijske bolesti srca.
Keywords:
myocardial ischemia / atherosclerosis / endothelial dysfunction / Th1/Th2 balans / Th17/Treg balans / ishemija miokarda / ateroskleroza / disfunkcija endotela / Th1/Th2 balans / Th17/Treg balansSource:
Arhiv za farmaciju, 2008, 58, 5-6, 307-323Publisher:
- Savez farmaceutskih udruženja Srbije, Beograd
Collections
Institution/Community
PharmacyTY - JOUR AU - Leposavić, Gordana PY - 2008 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1153 AB - Ischemic heart disease (IHD) is a condition in which there is an inadequate supply of blood and oxygen to a portion of the myocardium; it typically occurs when there is an imbalance between myocardial oxygen supply and demand. The most common cause of myocardial ischemia is atherosclerotic disease of an epicardial coronary artery (or arteries) sufficient to cause a regional reduction in myocardial blood flow and inadequate perfusion of the myocardium supplied by the involved coronary artery. Although risk factors for atherosclerosis development are largely known, the pathogenesis of disease is still matter of discussion. The investigation during the last decades have provided new date related to the role of endothelial dysfunction, and particularly role of immune cell-mediated mechanisms in pathogenesis of the disease. The data elucidating role of immunopathogenetic mechanisms in the development of atherosclerotic lesions and their complications provided a strong basis for designing a new generation of drugs to combat aterosclerosis, and thereby to prevent ischemic heart disease. AB - Ishemijsku bolest srca karakteriše nedovoljno snabdevenje krvlju, odnosno kiseonikom, dela miokarda. Nastaje onda kada postoji nesklad između količine kiseonika koja se doprema cirkulacijom u miokard i njegovih potreba u kiseoniku. Najčešći uzrok smanjenog snabdevanja krvlju miokarda je aterosklerotska bolest jedne ili više epikardnih koronarnih arterija, koja sužava lumen i, sledstveno smanjuje. Iako su faktori rizika za razvoj ateroskleroze uglavnom poznati mehanizmi razvoja aterosklerotskih promena još uvek nisu u potpunosti razjašnjeni. Poslednje decenije donele su niz novih saznanja, vezanih za ulogu disfunkcije endotela u inicijaciji i progresiji ateroskerotskih promena i posebno za ulogu ćelija imunskog sistema i imunskih mehanizama u patogenezi ovog oboljenja. Saznanja vezana za ulogu imunopatogenetskih mehanizana stvorila su značajnu osnovu za dizajniranje nove generacije lekova za terapiju aterosklerose i time prevencu ishemijske bolesti srca. PB - Savez farmaceutskih udruženja Srbije, Beograd T2 - Arhiv za farmaciju T1 - Etiology and patogenesis of ischemic heart disease T1 - Etiologija i patogeneza ishemijske bolesti srca VL - 58 IS - 5-6 SP - 307 EP - 323 UR - https://hdl.handle.net/21.15107/rcub_farfar_1153 ER -
@article{ author = "Leposavić, Gordana", year = "2008", abstract = "Ischemic heart disease (IHD) is a condition in which there is an inadequate supply of blood and oxygen to a portion of the myocardium; it typically occurs when there is an imbalance between myocardial oxygen supply and demand. The most common cause of myocardial ischemia is atherosclerotic disease of an epicardial coronary artery (or arteries) sufficient to cause a regional reduction in myocardial blood flow and inadequate perfusion of the myocardium supplied by the involved coronary artery. Although risk factors for atherosclerosis development are largely known, the pathogenesis of disease is still matter of discussion. The investigation during the last decades have provided new date related to the role of endothelial dysfunction, and particularly role of immune cell-mediated mechanisms in pathogenesis of the disease. The data elucidating role of immunopathogenetic mechanisms in the development of atherosclerotic lesions and their complications provided a strong basis for designing a new generation of drugs to combat aterosclerosis, and thereby to prevent ischemic heart disease., Ishemijsku bolest srca karakteriše nedovoljno snabdevenje krvlju, odnosno kiseonikom, dela miokarda. Nastaje onda kada postoji nesklad između količine kiseonika koja se doprema cirkulacijom u miokard i njegovih potreba u kiseoniku. Najčešći uzrok smanjenog snabdevanja krvlju miokarda je aterosklerotska bolest jedne ili više epikardnih koronarnih arterija, koja sužava lumen i, sledstveno smanjuje. Iako su faktori rizika za razvoj ateroskleroze uglavnom poznati mehanizmi razvoja aterosklerotskih promena još uvek nisu u potpunosti razjašnjeni. Poslednje decenije donele su niz novih saznanja, vezanih za ulogu disfunkcije endotela u inicijaciji i progresiji ateroskerotskih promena i posebno za ulogu ćelija imunskog sistema i imunskih mehanizama u patogenezi ovog oboljenja. Saznanja vezana za ulogu imunopatogenetskih mehanizana stvorila su značajnu osnovu za dizajniranje nove generacije lekova za terapiju aterosklerose i time prevencu ishemijske bolesti srca.", publisher = "Savez farmaceutskih udruženja Srbije, Beograd", journal = "Arhiv za farmaciju", title = "Etiology and patogenesis of ischemic heart disease, Etiologija i patogeneza ishemijske bolesti srca", volume = "58", number = "5-6", pages = "307-323", url = "https://hdl.handle.net/21.15107/rcub_farfar_1153" }
Leposavić, G.. (2008). Etiology and patogenesis of ischemic heart disease. in Arhiv za farmaciju Savez farmaceutskih udruženja Srbije, Beograd., 58(5-6), 307-323. https://hdl.handle.net/21.15107/rcub_farfar_1153
Leposavić G. Etiology and patogenesis of ischemic heart disease. in Arhiv za farmaciju. 2008;58(5-6):307-323. https://hdl.handle.net/21.15107/rcub_farfar_1153 .
Leposavić, Gordana, "Etiology and patogenesis of ischemic heart disease" in Arhiv za farmaciju, 58, no. 5-6 (2008):307-323, https://hdl.handle.net/21.15107/rcub_farfar_1153 .